Autologous CAR-T cells Therapy(UTC Therapeutics Inc)

N/A

Report date: 2022/12/27 12:28:06

Base Information

Drug NameAutologous CAR-T cells Therapy(UTC Therapeutics Inc)
Drug Alias NameAutologous CAR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsBone Marrow NeoplasmsHematologic NeoplasmsMultiple Myeloma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesUTC Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUTC Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBone Marrow NeoplasmsHematologic NeoplasmsLymphoma +[5] 
Inactive IndicationsMultiple MyelomaLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeN/A
Related LinksN/A